Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors
OncLive - 28 Apr 2025Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors ...
dostarlimab
Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors ...
Dostarlimab: Review on success story and clinical trials
ScienceDirect.com - 08 Jan 2025Dostarlimab: Review on success story and clinical trials ...
A New Immune Treatment May Work Against Several Cancer Types
Time Magazine - 28 Apr 2025A New Immune Treatment May Work Against Several Cancer Types ...
AACR 2025: High Response Rates With Dostarlimab Suggest New Standard for dMMR Treatment
Pharmacy Times - 28 Apr 2025AACR 2025: High Response Rates With Dostarlimab Suggest New Standard for dMMR Treatment ...
Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer
CancerNetwork - 20 Jan 2025Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer ...
Nature Journal Validates Cancer Breakthrough in Ovarian and Colorectal Treatment Study | LIXTW Stock News
Stock Titan - 09 Jul 2025Nature Journal Validates Cancer Breakthrough in Ovarian and Colorectal Treatment Study | LIXTW Stock News ...
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
Targeted Oncology - 16 Dec 2024FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer ...
STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi’s Sarcoma
BMC Cancer - 01 Jul 2025STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi’s Sarcoma ...
Early-Onset, Severe Immune-Mediated Hepatitis With Dostarlimab in a Patient With Endometrial Cancer: A Case Report
Journal of Hematology Oncology Pharmacy - 07 Apr 2025Early-Onset, Severe Immune-Mediated Hepatitis With Dostarlimab in a Patient With Endometrial Cancer: A Case Report ...
Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer
OncLive - 17 Mar 2025Dostarlimab/Chemo Improves Long-Term DOR in Advanced Endometrial Cancer ...
Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial
CancerNetwork - 20 Mar 2025Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial ...
Dr Lantsman on Future Directions for Evaluating Dostarlimab/Chemo in Endometrial Cancer
OncLive - 23 May 2025Dr Lantsman on Future Directions for Evaluating Dostarlimab/Chemo in Endometrial Cancer ...
Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer
OncLive - 17 Mar 2025Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer ...
European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer
OncLive - 20 Jan 2025European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer ...
Dostarlimab Yields High cCR Rates and Organ Preservation in Early-Stage dMMR Tumors
OncLive - 09 May 2025Dostarlimab Yields High cCR Rates and Organ Preservation in Early-Stage dMMR Tumors ...
Dostarlimab Plus Chemo With Maintenance Niraparib Generates Modest PFS Boost in Advanced Ovarian Cancer
OncLive - 02 Jun 2025Dostarlimab Plus Chemo With Maintenance Niraparib Generates Modest PFS Boost in Advanced Ovarian Cancer ...
Dostarlimab Plus Cobolimab Improves MPR Rate vs Dostarlimab in High-Risk Resectable Melanoma
OncLive - 03 Jun 2025Dostarlimab Plus Cobolimab Improves MPR Rate vs Dostarlimab in High-Risk Resectable Melanoma ...
FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer
OncLive - 18 Dec 2024FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer ...
Frontline Belrestotug Plus Dostarlimab Misses PFS End Point in PD-L1–High NSCLC
OncLive - 13 May 2025Frontline Belrestotug Plus Dostarlimab Misses PFS End Point in PD-L1–High NSCLC ...